Updates

Brave Bison

February 2025

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Since my last update, BBSN has announced its sixth acquisition. It has also bought Engage Digital Partners, a sports marketing agency specialising in fan engagement campaigns, which has been on the block since last summer. Engage counts the ICC and its cricket tournament properties including the current Men's T20 World Cup in the USA and West Indies as clients. It also works with the New Zealand All Blacks and Real Madrid to help monetise their vast fan bases through digital content. BBSN is paying up to £10.6m with an initial payment of £2.1m. Engage is to be combined with Brave Bison’s existing network of channels, which already benefits from partners such as PGA Tour, Ryder Cup, US Open, Australian Open, CPLT20 and Le Mans. Sal ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Alliance Pharma

IG Design

Brave Bison (April 2025)

Brave Bison (October 2024)

Brave Bison (September 2024)

Brave Bison (July 2024)

Brave Bison (October 2023)

Brave Bison (June 2023)

Brave Bison - High growth and exciting (February 2023)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X